{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.6"},{"groupId":"OG001","value":"96.6"},{"groupId":"OG002","value":"95.3"}]}],"title":"AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0"},{"groupId":"OG001","value":"23.7"},{"groupId":"OG002","value":"27.9"}]}],"title":"SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"43"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence associated with the use of a drug in participants, whether or not considered drug related. An AE or suspected adverse reaction is considered serious (an SAE) if it is fatal, life-threatening, causes in-patient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect in a neonate/infant born to a mother or father exposed to study treatment or is an important medical event. Treatment-emergent adverse events are reported.","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.","id":"OG000","title":"AG-120"},{"description":"Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.","id":"OG001","title":"Placebo"},{"description":"Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle for up to approximately 32 months.","id":"OG002","title":"After Crossover to AG-120"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set (SAS) included all participants who received at least one dose of study drug (AG-120 or Placebo).","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to 28 days after last dose for each intervention (Up to approximately 4 Years)","title":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}